Omissions, biases, and nondisclosed conflicts of interest: Is there a hidden agenda in the NAMS position statement?

MedGenMed Medscape General Medicine

Volumn 7, Issue 3, 2005, Pages

  Tiefer, Leonore ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADVISORY COMMITTEE; ARTICLE; CONFLICT OF INTEREST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EUROPEAN UNION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH PROMOTION; HORMONE SUBSTITUTION; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRESCRIPTION; SEXUAL DYSFUNCTION; SEXUALITY; WOMEN'S HEALTH; EPIDEMIOLOGY; MENOPAUSE; PHYSIOLOGY; UNITED STATES;

BIAS (EPIDEMIOLOGY); CONFLICT OF INTEREST; FEMALE; HUMANS; MENOPAUSE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SOCIETIES, MEDICAL; TESTOSTERONE; UNITED STATES;

EID: 33750320888     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Use of Testosterone Therapy by Postmenopausal Women: Position Statement of the North American Menopause Society. September 8, 2005. Available at: http://www.prdirect.ca/en/view_release.aspx?TrafficID=3998. Accessed 9/19/05.
2. NAMS Board of Trustees. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause. 2005;12:497-511 [Epub ahead of print]. Available at: http://www.menopause.org/aboutmeno/PStestosterone.pdf. Accessed 9/19/05.
3. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Advisory Committee For Reproductive Health Drugs. Transcript of the committee meeting for the new drug application, the testosterone transdermal system, Procter & Gamble, December 2, 2004. Available at: http://www.fda.gov/ohrms/dockets/ ac/04/transcripts/2004-4082T1.htm.Accessed 9/19/05.
4. FDA Hearing on Intrinsa, Dec. 2, 2004. New View Resources. Available at: http://www.fsd-alert.org/intrinsa.html. Accessed 9/19/05.
5. Peale C. P & G withdraws Intrinsa application. The Enquirer, December 21, 2004. Available at: http://news.enguirer.com/apps/pbcs.dll/ article?AID=/20041221/BIZ01/412220309. Accessed 9/19/05.
6. Young A, Adams C. 'Off-label' drugs take their toll. Knight Ridder Newspapers, November 2, 2003. Available at: http://www.realcities.com/ mid/krwashington/news/special_packages/riskyrx/116/7146578.htm. Accessed 9/20/05.
7. Adams C, Young A. Drug-makers' promotions boost off-label use by doctors. Knight Ridder Newspapers, November 3, 2003. Availiable at: http://www.realcities.com/mid/krwashington/news/special_packages/ riskyrx/116/7152480.htm. Accessed 9/20/05.
8. Adams C, Young A. FDA oversight of 'off-label' drug use wanes. Knight Ridder Newspapers, November 4, 2003. Availiable at: http://www.realcities.com/mid/krwashington/news/special_packages/ riskyrx/116/7152542.htm. Accessed 9/20/05.
9. Mehlman MJ. Off-label prescribing. The Doctor Will See You Now. May 2005. Availiable at: http://www.thedoctorwillseeyounow.com/articles/ bioethics/offlabel_11/. Accessed 9/20/05.
10. Crawford L. Meeting Women's Desire for Desire. Testosterone Fix Risky, Say Some Experts. Washington Post, September 20, 2005. Available at: http://www.washingtonpost.com/wp-dyn/content/article/2005/09/19/ AR2005091901235.html. Accessed 9/20/05.
11. Freeman MP. Testosterone supplementation in women: prescribing practices in one community. J Womens Health (Larchmt). 2004; 13:239-240.
12. La commercialisation du "Viagra féminin" est rejetée. Le Monde, February, 2, 2005. Available at: http://www.lemonde.fr/cgi-bin/ACHATS/ acheter.cgi?offre=ARCHIVES&typeitem=ART_ARCH_30J&objet_id=890551. Accessed 9/19/05.
13. Anderson M. Is lack of sexual desire a disease? Is testosterone the cure? Medscape Ob/Gyn & Women's Health. 2005;10(2). Available at: http://www.medscape.com/viewarticle/512218. Accessed 9/19/05.